GYG1
Basic information
Region (hg38): 3:148991408-149031775
Previous symbols: [ "GYG" ]
Links
Phenotypes
GenCC
Source:
- glycogen storage disease XV (Strong), mode of inheritance: AR
- polyglucosan body myopathy type 2 (Definitive), mode of inheritance: AR
- glycogen storage disease XV (Strong), mode of inheritance: AR
- polyglucosan body myopathy type 2 (Strong), mode of inheritance: AR
- glycogen storage disease XV (Supportive), mode of inheritance: AR
- polyglucosan body myopathy type 2 (Supportive), mode of inheritance: AR
- glycogen storage disease XV (Strong), mode of inheritance: AR
- polyglucosan body myopathy type 2 (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Glycogen storage disease XV | AR | Cardiovascular | Surveillance to allow early diagnosis and treatment of cardiac complications (eg, treatment of heart failure and arrhythmias via medical management and ICD placement) may be beneficial | Biochemical; Cardiovascular; Musculoskeletal | 20357282; 25272951 |
ClinVar
This is a list of variants' phenotypes submitted to
- Glycogen storage disease XV;Polyglucosan body myopathy type 2 (9 variants)
- Polyglucosan body myopathy type 2;Glycogen storage disease XV (8 variants)
- not provided (2 variants)
- Glycogen storage disease XV (1 variants)
- Polyglucosan body myopathy type 2 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GYG1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 40 | 45 | ||||
missense | 103 | 11 | 115 | |||
nonsense | 13 | |||||
start loss | 2 | |||||
frameshift | 11 | |||||
inframe indel | 3 | |||||
splice donor/acceptor (+/-2bp) | 5 | |||||
splice region | 1 | 3 | 5 | 9 | ||
non coding | 42 | 23 | 66 | |||
Total | 17 | 9 | 113 | 93 | 28 |
Highest pathogenic variant AF is 0.000420
Variants in GYG1
This is a list of pathogenic ClinVar variants found in the GYG1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-148991479-A-G | Likely benign (May 19, 2019) | |||
3-148991537-G-A | Benign (Sep 18, 2018) | |||
3-148991568-C-G | Likely benign (May 15, 2019) | |||
3-148991599-CA-C | not specified | Likely benign (Nov 18, 2016) | ||
3-148991642-T-A | Glycogen storage disease XV;Polyglucosan body myopathy type 2 | Uncertain significance (Oct 13, 2022) | ||
3-148991643-G-C | Polyglucosan body myopathy type 2;Glycogen storage disease XV | Likely pathogenic (Jun 30, 2021) | ||
3-148991645-C-G | Glycogen storage disease XV;Polyglucosan body myopathy type 2 | Uncertain significance (Mar 14, 2022) | ||
3-148991648-G-A | Polyglucosan body myopathy type 2 • Polyglucosan body myopathy type 2;Glycogen storage disease XV | Likely pathogenic (Dec 09, 2023) | ||
3-148991649-T-C | Polyglucosan body myopathy type 2 • Polyglucosan body myopathy type 2;Glycogen storage disease XV | Likely pathogenic (Oct 26, 2023) | ||
3-148991655-C-T | Glycogen storage disease XV;Polyglucosan body myopathy type 2 | Likely benign (Nov 14, 2022) | ||
3-148991664-C-G | Glycogen storage disease XV;Polyglucosan body myopathy type 2 | Likely benign (Sep 08, 2023) | ||
3-148991743-C-G | Benign (Jun 14, 2018) | |||
3-148991963-G-A | Benign (Jun 14, 2018) | |||
3-148994127-T-C | Polyglucosan body myopathy type 2;Glycogen storage disease XV | Likely benign (Jul 04, 2021) | ||
3-148994129-T-C | Glycogen storage disease XV;Polyglucosan body myopathy type 2 | Likely benign (Nov 22, 2022) | ||
3-148994144-C-T | Glycogen storage disease XV;Polyglucosan body myopathy type 2 | Pathogenic (Apr 03, 2023) | ||
3-148994148-C-T | Uncertain significance (Jun 01, 2024) | |||
3-148994159-C-G | Glycogen storage disease XV;Polyglucosan body myopathy type 2 | Uncertain significance (Jun 10, 2021) | ||
3-148994159-C-T | Glycogen storage disease XV;Polyglucosan body myopathy type 2 | Likely benign (Oct 17, 2023) | ||
3-148994159-C-CT | Glycogen storage disease XV;Polyglucosan body myopathy type 2 | Pathogenic (Oct 17, 2023) | ||
3-148994170-C-G | Polyglucosan body myopathy type 2;Glycogen storage disease XV | Uncertain significance (Dec 02, 2021) | ||
3-148994179-C-T | Polyglucosan body myopathy type 2;Glycogen storage disease XV | Likely benign (Jul 22, 2022) | ||
3-148994180-G-A | Polyglucosan body myopathy type 2;Glycogen storage disease XV • Inborn genetic diseases | Conflicting classifications of pathogenicity (Jan 06, 2024) | ||
3-148994189-G-T | Glycogen storage disease XV;Polyglucosan body myopathy type 2 • Inborn genetic diseases | Uncertain significance (Jul 06, 2022) | ||
3-148994190-C-T | Glycogen storage disease XV;Polyglucosan body myopathy type 2 | Uncertain significance (Feb 06, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GYG1 | protein_coding | protein_coding | ENST00000345003 | 8 | 36292 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
4.83e-12 | 0.0553 | 125568 | 0 | 180 | 125748 | 0.000716 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.0645 | 185 | 187 | 0.987 | 0.00000949 | 2283 |
Missense in Polyphen | 79 | 76.446 | 1.0334 | 968 | ||
Synonymous | 0.703 | 68 | 75.8 | 0.897 | 0.00000435 | 680 |
Loss of Function | 0.211 | 18 | 19.0 | 0.948 | 0.00000101 | 211 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000797 | 0.000795 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000435 | 0.000435 |
Finnish | 0.000554 | 0.000554 |
European (Non-Finnish) | 0.00103 | 0.00103 |
Middle Eastern | 0.000435 | 0.000435 |
South Asian | 0.000490 | 0.000490 |
Other | 0.000816 | 0.000815 |
dbNSFP
Source:
- Function
- FUNCTION: Self-glucosylates, via an inter-subunit mechanism, to form an oligosaccharide primer that serves as substrate for glycogen synthase.;
- Disease
- DISEASE: Glycogen storage disease 15 (GSD15) [MIM:613507]: A metabolic disorder resulting in muscle weakness, associated with the glycogen depletion in skeletal muscle, and cardiac arrhythmia, associated with the accumulation of abnormal storage material in the heart. The skeletal muscle shows a marked predominance of slow-twitch, oxidative muscle fibers and mitochondrial proliferation. {ECO:0000269|PubMed:20357282}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Polyglucosan body myopathy 2 (PGBM2) [MIM:616199]: A glycogen storage disease characterized by polyglucosan accumulation in muscle, and skeletal myopathy without cardiac involvement. Most patients manifest slowly progressive, hip girdle, shoulder girdle, and/or hand and leg muscle weakness. Polyglucosan contains abnormally long and poorly branched glucosyl chains and is variably resistant to digestion by alpha-amylase. {ECO:0000269|PubMed:25272951}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Starch and sucrose metabolism - Homo sapiens (human);Insulin Signaling;Glycogen Metabolism;Neutrophil degranulation;Metabolism of carbohydrates;Innate Immune System;Immune System;Metabolism;glycogen biosynthesis;Glycogen breakdown (glycogenolysis);Glycogen synthesis;Glycogen metabolism
(Consensus)
Recessive Scores
- pRec
- 0.164
Intolerance Scores
- loftool
- 0.977
- rvis_EVS
- -0.07
- rvis_percentile_EVS
- 48.54
Haploinsufficiency Scores
- pHI
- 0.173
- hipred
- N
- hipred_score
- 0.396
- ghis
- 0.471
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.399
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gyg
- Phenotype
- mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan);
Gene ontology
- Biological process
- glycogen biosynthetic process;neutrophil degranulation
- Cellular component
- extracellular region;cytosol;membrane;secretory granule lumen;lysosomal lumen;ficolin-1-rich granule lumen
- Molecular function
- protein binding;glycogenin glucosyltransferase activity;metal ion binding;UDP-alpha-D-glucose:glucosyl-glycogenin alpha-D-glucosyltransferase activity